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Diabetes is characterized by elevated blood glucose (BG) due to autoimmune destruction of insulin-producing β-
cells (type 1; T1D) or extensive β-cell apoptosis owed to insulin resistance (type 2; T2D). Over 29 million people 
in the US suffer from diabetes and its complications including blindness, kidney failure and stroke making this 
the single most expensive disease with total costs of $327 billion in 2017. Pharmacological interventions are 
linked to serious side effects, are incompatible with abnormal kidney or liver function and their molecular targets 
have low tissue specificity (e.g. sulfonylurea-targeted ATP-dependent K+ channels). Daily administration of 
insulin is essential for the survival of T1D and advanced T2D patients but imposes significant lifestyle 
restrictions, may cause hypoglycemia, and does not reverse the long-term crippling effects of the disease. 
Additionally, agents promoting pancreatic endocrine cell regeneration remain elusive. Therefore, novel 
strategies to achieve BG homeostasis in a glucose-dependent fashion without side effects are highly desirable. 
Optogenetic technologies allow the drug-free 
manipulation of diverse cellular functions 
through modulation of molecular moieties with 
unique spatiotemporal precision. One such 
moiety is cyclic AMP (cAMP), which is an 
amplifier of glucose-stimulated insulin secretion 
(GSIS) in β-cells. To this end, we engineered 
pancreatic β-cells and primary islets to express 
a photoactivatable adenylyl cyclase (PAC)1. 
PAC-expressing cells exhibited a greater than 5 
times rise in cAMP within 5 min of 
photoactivation and a rapid drop (~12 min) 
upon termination of illumination. This led to a 2- 
to 3-fold increase of GSIS in PAC-positive β-
cells or islets exposed to blue light vs. those 
kept in dark (Fig. 1A). Cells exhibited 
consistently enhanced GSIS over multiple 
rounds of photoactivation without changes in 
viability. The pronounced response was 
comparable to that by β-cells treated with 
known secretagogues including adenylyl 
cyclase activators or phosphodiesterase 
inhibitors1. No difference was observed in 
insulin release with or without illumination in the absence of glucose, further justifying the optogenetic targeting 
of cAMP, which augments but does not induce hormone secretion. The dependence of GSIS on Ca2+ signaling 
remained intact in engineered β-cells. Light-stimulated secretion of insulin was an order of magnitude greater 
when PAC-expressing β-cells formed clusters (termed ‘pseudoislets’; PIs). The function of PIs carrying PAC was 
tested in vivo. Encapsulated PIs were delivered subcutaneously to mice, which were rendered diabetic upon 
treatment with streptozotocin (STZ; Fig. 1B). The animals were subjected to a glucose tolerance test (GTT) 
following a 6-h fasting and intraperitoneal injection of glucose. Blood was sampled before (0 min) and after 
glucose injection (30, 60, 90 and 120 min) and BG was determined using a glucometer. The mice were exposed 
to blue light for 3 h starting 1 h before the GTT (Fig. 1C). Animals receiving PAC-expressing β-cells exhibited 
impaired glucose tolerance in the absence of illumination while the BG returned to baseline in mice with 
engineered cells undergoing photostimulation.  
Currently, a bioartificial pancreas device (Fig. 1D) is developed integrating β-cells amenable to optogenetic 
regulation of GSIS, glucose biosensing and remotely powered and controlled microLEDs for GSIS 
enhancement. 
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(A) Insulin secretion and cAMP of murine islets with (white) or 
without PAC (gray). *p<0.01 PAC+ vs. PAC- islets in matching 
glucose levels. ANOVA and Tukey post hoc test were 
performed. **p<0.01, PAC+ islets at 20.2 vs. 2.8 mM glucose1. 
(B) Encapsulated PIs of PAC+ β-cells (bar: 100 m) delivered 
to STZ-treated mice. Blue LED array (1 ft2) is shown. (C) GTT 
data (mean±SEM, 5 mice/group) for STZ-treated mice 
exposed to light (lower curve) or not (upper curve). Student’s 
2-tailed unpaired t-test was applied with the Holm-Šídák post 
hoc test. ***p<0.005 for +light vs. -light. (D) Optogenetic 
bioartificial pancreas device that is currently being tested. 
